Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Sara Petta"'
Autor:
Manuela Mancini, Sara Petta, Valentina Corradi, Maurizio Botta, Maria Alessandra Santucci, Fabrizio Manetti
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 20:6133-6137
An in silico structure-based ligand design approach resulted in the identification of the first non-peptidic small molecule able to inhibit protein-protein interactions between 14-3-3 and c-Abl. This compound shows an anti-proliferative effect on hum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7213505c283725989cde31e875e1ed9
https://doi.org/10.1016/j.bmcl.2010.08.019
https://doi.org/10.1016/j.bmcl.2010.08.019
Autor:
Enza Barbieri, Giovanni Martinelli, Maria Alessandra Santucci, Valentina Corradi, Manuela Mancini, Sara Petta
Publikováno v:
Leukemia Research. 34:641-648
Constitutive tyrosine kinase (TK) activity of p210 BCR-ABL fusion protein of chronic myeloid leukemia (CML) usurps physiological functions of normal p145 c-ABL protein. Accordingly, its inhibition by imatinib mesylate (IM) lets p145 c-ABL translocate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f75240b6d6fe330167b156b2578b173
https://doi.org/10.1016/j.leukres.2009.07.012
https://doi.org/10.1016/j.leukres.2009.07.012
Autor:
Enza Barbieri, Fabrizio Manetti, Manuela Mancini, Sara Petta, Valentina Corradi, Maurizio Botta, Maria Alessandra Santucci
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 336(3)
Resistance of chronic myeloid leukemia (CML) to tyrosine kinase inhibitor imatinib mesylate (IM) is most often due to point mutations in the Bcr-Abl fusion gene. T315I mutation (resulting in substitution of Ile for a Thr residue at the “gatekeeper
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30527b8e342430d50f9fa27a357d9c65
https://pubmed.ncbi.nlm.nih.gov/21041536
https://pubmed.ncbi.nlm.nih.gov/21041536
Autor:
Ilaria Iacobucci, Sara Petta, Enza Barbieri, Valentina Salvestrini, Maria Alessandra Santucci, Manuela Mancini
Slug, a Snail-related zinc-finger transcription factor implicated in the increased motility of mesenchymal cells during embryonic development and progression of cancer cells towards an invasive phenotype, plays a specific and critical role in the pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::615320d0c5ab5f2ff7b7a50f8e182d43
http://hdl.handle.net/11585/96724
http://hdl.handle.net/11585/96724
Publikováno v:
Journal of Cellular Biochemistry.
The mammalian target of rapamycin (mTOR) is one target of BCR-ABL fusion gene of chronic myeloid leukemia (CML). Moreover, it drives a compensatory route to Imatinib mesylate (IM) possibly involved in the progression of leukemic progenitors towards a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c42614eb68d1d6fd02de269bc826002b
https://doi.org/10.1002/jcb.22380
https://doi.org/10.1002/jcb.22380
Autor:
Maria Alessandra Santucci, Patrizia Corrado, Sara Petta, Manuela Mancini, Giovanni Martinelli, Gianluca Brusa, Enza Barbieri
Publikováno v:
Leukemia. 23(2)
Acetylation of FOXO3a transcription factor in response to imatinib of chronic myeloid leukemia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::934726c7fbd78285c4d08d20da1d643f
https://pubmed.ncbi.nlm.nih.gov/18685617
https://pubmed.ncbi.nlm.nih.gov/18685617
Autor:
Patrizia Corrado, Eleonora Pagnotta, Sara Petta, Gianluca Brusa, Maria Alessandra Santucci, Manuela Mancini, Elisa Zuffa
Publikováno v:
Blood. 108:2133-2133
Nuclear accumulation of c-Abl protein in response to genotoxic damage addresses apoptotic cell death. The process, driven by the disruption of its binding to 14-3-3 scaffolding proteins, is independent from c-Abl catalytic state and conditional upon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c896ceed3b3550b17005668a1991f1f
https://doi.org/10.1182/blood.v108.11.2133.2133
https://doi.org/10.1182/blood.v108.11.2133.2133
Autor:
Pankaj Pandey, Kuldeep K. Roy, Haining Liu, Guoyi Ma, Sara Pettaway, Walid F. Alsharif, Rama S. Gadepalli, John M. Rimoldi, Christopher R. McCurdy, Stephen J. Cutler, Robert J. Doerksen
Publikováno v:
Molecules, Vol 23, Iss 10, p 2630 (2018)
Natural products are an abundant source of potential drugs, and their diversity makes them a rich and viable prospective source of bioactive cannabinoid ligands. Cannabinoid receptor 1 (CB1) antagonists are clinically established and well documented
Externí odkaz:
https://doaj.org/article/d0647e58bce14f2e991041232d68a234